Session Title: Quick Fire Free Paper 1
Session Date/Time: Thursday 11/09/2014 | 08:00-10:00
Paper Time: 08:15
Venue: Boulevard D
First Author: : K.Nabawi EGYPT
Co Author(s): : A. Sharaf H. Sowelam
study of 1 week and 1 month spectral domain optical coherence tomography(SD-OCT) central macular thickness (CMT) and visual acuity (VA) changes post injection of intravitreal ranibizumab in eyes with diabetic macular edema (DME).
71 eyes of 62 patients recruited at the outpatient ophthalmology clinic at Alexandria university hospital.
history taking, and ophthalmic examination (including fundus biomicroscopy, SD-OCT, and VA) were done at presentation, 1 week, and 1 month post intravitreal ranibizumab injection (0.5mg/0.05ml). Eyes were subtyped according to the type of macular edema (spongiform, cystic, and subretinal fluid SRF). Also, the presence/absence of epiretinal membrane (ERM) was recorded.
Eyes with all types of retinal edema showed significant reduction of CMT at 1 week and 1 month post injection. Those with SRF were the most significant (477M-447M-386M), cystic (439M-358M-332M), then spongiform (298M-285M-272M). Eyes with ERM showed non-significant decrease in CMT (381M-358M-312M). VA improvement was most significant in eyes with cystic and SRF at 1 month post injection. Yet, eyes with spongiform edema and ERM showed non-significant VA gain.
patients with DME can be counseled before intravitreal ranibizumab injection depending on their subtype of macular edema for short-term improvement in their VA and CMT. Eyes with cystic edema and SRF gain the most benefit as compared to eyes with spongiform edema and those with ERM.